Authors

• Guenther Koehne, Miami Cancer InstituteFollow

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)

Publication Date

10-1-2025

Content Type

article

PubMed ID:

41129765

Additional Authors:

Additional Authors and Institutional Affiliations

Citation

Koehne, G., Mushtaq, M. U., Muffly, L. S., Menes, M., Azzi, J., Bernard, L., Cooper, B., Kennedy, V., Koura, D., Maakaron, J., Magenau, J., McClune, B., Patel, S. S., Rimando, J. C., Shah, N. N., Suh, H. C., Tamari, R., Thosar, S., Canesin, G., Hyzy, S. L., … DiPersio, J. F. (2025). Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). JCO precision oncology, 9, e2500556. https://doi.org/10.1200/PO-25-00556